Search Medical Condition
Please enter condition
Please choose location from dropdown

Hradec Kravlove, Czech Republic Clinical Trials

A listing of Hradec Kravlove, Czech Republic clinical trials actively recruiting patients volunteers.

RESULTS

Found (139) clinical trials

A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

Evaluating efficacy & safety of lacosamide versus Placebo in a blinded fashion as add-on Therapy for Primary Generalized Tonic-clonic (PGTC) seizures in subject 4 years of age with idiopathic generalized epilepsy currently taking 1 to 3 antiepileptic drugs. Maximum duration of study drug administration is 28 weeks. Eligible subjects may ...

Phase

0.0 miles

Learn More »

Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML

In the first part of the trial, patients will be randomly assigned to receive either 90 mg/m2 or 60 mg/m2 daunorubicin in the first induction cycle in addition to standard dosed cytarabine. Assuming a superiority of 90 mg/m2, 436 patients will be recruited. In the second part of the trial, ...

Phase

0.0 miles

Learn More »

The Role of HE4 in the Follow-up of Advanced Ovarian Fallopian Tube and Primary Peritoneal Cancer

Ovarian cancer (OC) is the second most common gynaecologic cancer and the leading cause of death from gynaecologic malignancy among women in industrialized countries. The global incidence in both developed and developing countries can be estimated as 165,000 new cases per year. A heavy difference in prognosis exists between the ...

Phase N/A

0.0 miles

Learn More »

Long-term Safety Follow-up After Growth Hormone Treatment of Short Children Born Small for Gestational Age

The purpose of this study is to monitor short children born SGA who were treated with growth hormone in study EP00-401 for the development of diabetes for a further 10 years after termination of growth hormone treatment and 2. to report the incidence of anti-rhGH antibodies and of E. coli ...

Phase N/A

0.0 miles

Learn More »

Efficacy Safety and Tolerability of Ancrod in Patients With Sudden Hearing Loss

The purpose of this study is to determine whether ancrod is effective and safe in the treatment of sudden sensorineural hearing loss (SSHL).

Phase

0.0 miles

Learn More »

Efficacy and Safety Study of BIIB074 in Participants With Small Fibre Neuropathy

The primary objective of this study is to evaluate the efficacy of BIIB074 in treating pain experienced by participants with confirmed small fibre neuropathy (SFN) that is idiopathic or associated with diabetes mellitus. The secondary objectives of this study are to evaluate the effect on worst pain, neuropathic pain quality, ...

Phase

0.0 miles

Learn More »

Study of Melflufen + Dex With Bortezomib or Daratumumab in Patients With RRMM

This is an open-label Phase 1/2a study which will enroll patients that have relapsed or relapsed-refractory multiple myeloma following 1-4 lines of prior therapy. Patients will receive either melflufen+dexamethasone+bortezomib or melflufen+dexamethasone+daratumumab and are required to be PI refractory to be enrolled to the bortezomib regimen, and to not have any ...

Phase

0.0 miles

Learn More »

Tysabri Observational Program

TOP is an epidemiological observational study of participants receiving natalizumab, with each participant to be followed for up to 10 years. This study is designed to address the long-term safety profile and the long-term impact on disease activity and progression of natalizumab with marketed use, and the impact of treatment ...

Phase N/A

0.91 miles

Learn More »

Endoscopic Pyloromyotomy for Refractory Gastroparesis

Gastroparesis is a disorder triggered by numerous causes and it is defined by symptoms and with an objective evidence of delayed gastric emptying in the absence of obstruction (albeit pyloric spasms may play a role in a subset of patients). Gastroparesis may be a consequence of medication, surgery or diabetes ...

Phase N/A

0.91 miles

Learn More »

Clinical Benefit of SAR650984 Bortezomib Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant

The duration of the study for each patient will include a screening period of up to 4 weeks, an induction period of 24 weeks (4 cycles with a duration of 42 4 days), a continuous treatment period and a crossover period (when applicable). The cycle duration is 28 4 days ...

Phase

0.91 miles

Learn More »